This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

17 Nov 2011

Takeda Initiates Phase II Clinical Trials of Quadrivalent Vaccine

Japan's Takeda Pharmaceutical has launched its phase II clinical trials of quadrivalent vaccine TAK-361S.

Takeda Pharmaceutical has initiated phase II clinical trials of quadrivalent vaccine TAK-361S in Japan.


TAK-361S is a combination of the combined diphtheria, tetanus, and acellular pertussis vaccine (trivalent vaccine) that has already been marketed by Takeda, and the inactivated poliovirus vaccine derived from Sabin strain (“Sabin-IPV”).


Polio, or acute poliomyelitis, is a viral infectious disease which is commonly referred to as infantile paralysis due to its high prevalence among children. In Japan, although live polio vaccine derived from attenuated Sabin-strain poliovirus has been used in periodic regular immunization, vaccine-associated paralytic poliomyelitis (VAPP) is found to develop in one of several million vaccine recipients, an

Related News